Abstract. Nuclear factor-κB (NF-κB) is widely involved in various lymphoid malignancies. However, its exact functional role and potential regulatory mechanisms in Hodgkin's lymphoma (HL) remains unclear. The present study aimed to investigate the regulatory mechanism of NF-κB in HL by analysis of a gene expression profile that was obtained from HL cells with or without NF-κB subunit 2 (NFKB2) knockdown. The GSE64234 dataset containing 6 HL cell line specimens transfected with small interfering (si)RNA against NFKB2 and 6 control specimens transfected with non-targeting siRNA sequences was downloaded from the Gene Expression Omnibus database. Based on these data, differentially expressed genes (DEGs) were screened for following data preprocessing. Functional enrichment analysis was subsequently conducted among the identified upregulated and downregulated DEGs. Additionally, a protein-protein interaction (PPI) network was constructed and module analyses were performed. Finally, microRNAs (miRNAs/miRs) targeting the identified DEGs were predicted for the construction of a miRNA-target regulatory network. A total of 253 DEGs were identified, consisting of 109 upregulated and 144 downregulated DEGs. Pathway enrichment analysis revealed that B-cell lymphoma 2-like 1 (BCL2L1) was significantly enriched in the NF-κB signaling pathway, and colony-stimulating factor 2 (CSF2) and BCL2L1 were enriched in the Jak-signal transducer and activator of transcription (STAT) signaling pathway. BCL2L1 and CSF2 were determined to be hub genes in the PPI network. A total of 6 miRNAs, including let-7a-5p, miR-9-5p, miR-155-5p, miR-135a-5p, miR-17-5p and miR-375, were identified in the miRNA-target regulatory network. The results of the present study indicated that NFKB2 may be involved in HL development through regulation of BCL2L1, CSF2, miR-135a-5p, miR-155-5p and miR-9-5p expression, as well as the modulation of Jak-STAT and NF-κB signaling pathways.
Introduction
Hodgkin's lymphoma (HL) is a common malignant tumor among adolescents (1) that is divided into classical and nodular lymphocyte predominant variants based on the 2008 World Health Organization classification (2) . Using chemotherapy and radiotherapy, alone or in combination, the durable remission rate for HL is ~60-80% (3, 4) . However, survivors have an increased risk of long-term sequelae, including cardiovascular disease and secondary malignancy (5, 6) . Therefore, understanding the underlying molecular mechanisms of HL development is essential for the discovery of novel therapeutic targets for HL.
Previous studies have demonstrated that the development and maintenance of various solid tumors and lymphoid malignancies is driven by nuclear factor-κB (NF-κB) (7, 8) . Constitutive NF-κB activation has been identified in classical HL (9) . A recent study by de Oliveira et al (10) investigated the functional roles and specific transcriptomes of NF-κB dimers with distinct subunit compositions by knockdown of NF-kB subunit 2 (NFKB2) in a HL cell line; it was reported that NFKB2 knockdown upregulated genes associated with hematopoietic and lymphoid organ development. NFKB2 is a member of the transcription factor complex NF-κB family, which promotes tumor cell proliferation and inhibits apoptosis (11) . Truncations in the C-terminal region of NKFB2 are closely associated with tumorigenesis in various hematopoietic tumors, including multiple myeloma, chronic lymphocytic leukemia and cutaneous T-cell lymphoma (12, 13) . A clear understanding of the regulatory role of NFKB2 in HL may contribute to the development of HL therapies.
de Oliveira et al (10) only analyzed the differentially expressed genes (DEGs) associated with NFKB2 knockdown in a HL cell line, and the regulatory mechanism of NFKB2 in HL remains poorly understood. Therefore, in the present study, the regulatory mechanism of NFKB2 in the tumorigenesis of HL was investigated by downloading the gene expression Analysis of NFKB2-mediated regulation of mechanisms underlying the development of Hodgkin's lymphoma data (GSE64234) deposited by de Oliveira et al (10) . DEGs between the NFKB2 knockdown and control groups were screened for prior to functional enrichment analysis of the identified DEGs, followed by protein-protein interaction (PPI) network and module analyses. Furthermore, microRNA (miRNA/miR) targets were predicted for the identified DEGs and a miRNA-target regulatory network was constructed.
Materials and methods
Affymetrix microarray data. The GSE64234 gene expression profile dataset deposited by de Oliveira et al (10) was downloaded from the Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/) database, which was based on the GPL6244 Affymetrix Human Gene miRNA-target regulatory network analysis. miRNAs have a major role in the regulation of biological processes in organisms (24) . Therefore, miRNAs that may target the identified DEGs were predicted using the 'gene-miRNA interaction information retrieval system' in miRWalk 2.0 (25) (http://mirwalk. uni-hd.de/), with a minimum seed length of seven and statistical significance set at P<0.05. miRWalk is a comprehensive database that not only documents miRNA binding sites within the complete sequence of a gene, but also combines this information with a comparison of binding sites resulting from 12 existing miRNA-target prediction programs (25) . In this study, the identified miRNA-target gene pairs required prediction by miRWalk, which included miRanda, miRDB 4.0, miRmap and TargetScan 6.2 databases. Predicted miRNAs were reviewed using the 'holistic view of validated disease-miRNA interactions' system in miRWalk 2.0 to select miRNAs that were confirmed to be associated with HL. These verified miRNA-target pairs were used to construct the regulatory network in Cytoscape (21) .
Results

DEG screening.
A total of 253 DEGs were identified following data preprocessing, which included 109 upregulated DEGs and 144 downregulated DEGs. The heat map clearly indicated the distinct separation of the knockdown and control groups (Fig. 1) .
Functional enrichment analyses. The upregulated DEGs were significantly enriched in 'platelet activation', 'osteoclast differentiation' and 'long-term depression' KEGG pathways, while downregulated DEGs were predominantly enriched in 'intestinal immune network for IgA production', 'HTLV-I infection' and 'NF-κB signaling pathway' KEGG pathways (Table I) . Additionally, upregulated DEGs were significantly enriched in 10 GO terms, including 'integral component of membrane', 'plasma membrane' and 'Golgi apparatus' terms ( Fig. 2A) . Downregulated DEGs were significantly enriched in 53 GO terms, including 'protein binding', 'cytoplasm', 'transcription factor activity' and 'sequence-specific DNA binding'. The top 15 downregulated GO terms are presented in Fig. 2B .
PPI network analysis. The PPI network included 142 nodes and 220 PPI pairs (Fig. 3) . Based on degree centrality analysis, 8 upregulated and 12 downregulated DEGs were determined to be hub genes (Table II) . KEGG pathway enrichment analysis was subsequently performed to investigate the function of the 20 identified hub genes. As presented in Table III , these hub genes were significantly enriched in 14 KEGG pathways. For instance, B-cell lymphoma 2-like 1 (BCL2L1) was significantly enriched in 'NF-κB signaling pathway' and 'Jak-STAT signaling pathway'. Colony-stimulating factor 2 (CSF2) was significantly enriched in 'transcriptional misregulation in cancer', 'TNF signaling pathway' and 'Jak-STAT signaling pathway'. Tyrosine kinase 2 was significantly enriched in 'Jak-STAT signaling pathway', 'toxoplasmosis', 'Epstein-Barr virus infection' and 'osteoclast differentiation'. CD44 antigen was enriched in 'Epstein-Barr virus infection'. A, B and C; Fig. 4 ). Module A was miRNA-target regulatory network analysis. The miRNA-target regulatory network was constructed with 32 nodes and 29 PPI pairs (Fig. 5) . Among the 32 nodes, there were 16 upregulated DEGs, 10 downregulated DEGs and 6 miRNAs, which included let-7a-5p, miR-9-5p, miR-155-5p, miR-135a-5p, miR-17-5p and miR-375.
Subnetwork module analysis. Module analysis identified three modules (termed
Discussion
In the present study, a total of 109 upregulated and 144 downregulated DEGs were identified between the NFKB2 knockdown and control groups. Pathway enrichment analysis revealed that BCL2L1 was significantly enriched in the NF-κB signaling pathway, and CSF2 and BCL2L1 were enriched in the Jak-STAT signaling pathway. Additionally, BCL2L1 and CSF2 were hub genes in the PPI network. Prediction of miRNA-target interactions identified 29 miRNA-target pairs involving in 6 miRNAs (let-7a-5p, miR-9-5p, miR-155-5p, miR-135a-5p, miR-17-5p and miR-375). The findings of the present study may provide guidelines for understanding the regulatory mechanism of NFKB2 and contribute to the identification of therapeutic targets for HL. BCL2L1 was demonstrated to be downregulated in HL cell lines following NFKB2 knockdown. This gene is a member of the Bcl-2 family and is a vital apoptosis-mediating gene that encodes both an antiapoptotic and proapoptotic splice variant (26) . Additionally, in the present study, module analysis revealed that BCL2L1 interacts with NFKB2 in module A, which indicated that knockdown of NFKB2 may suppress BCL2L1 expression and subsequently regulate HL cell apoptosis. Notably, this result was consistent with the findings of de Oliveira et al (10) , who reported that NFKB2 knockdown may downregulate BCL2L1 expression. Furthermore, BCL2L1 was enriched in the NF-κB signaling pathway in the present study. The NF-κB signaling pathway has been associated with the progression of several tumors, including HL (7, 11) . Therefore, it was speculated that BCL2L1 may be involved in NF-κB-dependent control of HL cell survival.
In addition to BCL2L1, CSF2 was also downregulated in the NFKB2 knockdown group. CSF2 encodes a cytokine that has been reported to be involved in the pathogenesis of HL (27) and is highly expressed in HL cells (28) . In accordance with these findings, the present study demonstrated that CSF2 was upregulated in HL control cells compared with HL cells with NFKB2 knockdown, indicating that NFKB2 may be involved in HL tumorigenesis through the upregulation of CSF2. KEGG pathway enrichment analysis revealed that CSF2 was enriched in the Jak-STAT signaling pathway. The Jak-STAT signaling pathway is regulated by a large array of cytokines and growth factors that induce proliferation or differentiation (29) . Activation of the Jak-STAT signaling pathway is a hallmark of various B-cell lymphomas, including classical HL (30) . Taken together, these data indicate that NFKB2 may be implicated HL development by regulating CSF2 expression, which in turn activates the Jak-STAT signaling pathway. miRNAs regulate gene expression and cellular processes (24) . They are also potential diagnostic and prognostic molecular markers in cancer, as well as targets for the development of highly specific therapies (31) . Based on the DEGs identified in the present study, several miRNAs were predicted. Among these, miR-135a-5p has been previously reported to have critical involvement in HL cell survival by targeting Jak2 (32) . Additionally, miR-155-5p has been recommended as a diagnostic marker in hematological tumors (33) . Notably, dysregulated expression of miR-155 has been reported in various types of lymphoma (33) . Differential expression of miR-9-5p has been demonstrated in hematological cell lines compared with normal lymphocyte populations (34) . Furthermore, a target gene of miR-9-5p, PR/SET domain 1, was reported to be downregulated in HL cells (35) , further indicating a potential role for miR-9-5p in HL. Therefore, NFKB2 may be implicated in HL development through interaction with these miRNAs.
In conclusion, the present study demonstrated that NFKB2 may be involved in the development of HL by interacting with several genes and miRNAs, including BCL2L1, CSF2, miR-135a-5p, miR-155-5p and miR-9-5p. Additionally, NFKB2-mediated modulation of the Jak-STAT and NF-κB signaling pathways may have a role in HL tumorigenesis. The genes, miRNAs and signaling pathways identified in the present study may serve as promising therapeutic targets for HL. Future experimental verification in vivo is required to confirm the findings of the present study. 
